Beccari et al. [29] tested the ObR antagonists Allo-aca, D-Ser, DDD and others, showing that the majority of tested leptin receptor antagonists reverse the leptin-stimulated proliferation of human breast cancer cells (MCF-7) and human colon adenocarcinoma cells (HT29). This evidence concerns the gene LEP and breast cancer.